phospholipase A1 member AGenealiases: PS-PLA1 · PSPLA1
Q-omics provides the consensus-scored PLA1A profile across patient tissues and cancer cell-line models. PLA1A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, PLA1A is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, PLA1A RNA expression shows 16,795 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight CESC, KIRC, and LSCC as cancer lineages where PLA1A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLA1A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLA1A survival associations across molecular data types. PLA1A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLA1A RNA expression–survival associations across cancer types. High PLA1A expression shows unfavorable associations in KIRP and ACC, but favorable associations in CESC, THCA, UVM and OV. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for PLA1A RNA expression.
This table summarizes PLA1A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PLA1A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLA1A shows lower tumor expression in LUAD and LUSC and higher tumor expression in KIRC, KIRP, COAD and STAD. The KIRC box plot shows higher PLA1A RNA expression in tumor versus normal tissue (log2 FC = +2.780, t-test p < 0.001).
This table shows molecular features associated with PLA1A in patient tissues and cancer cell lines. In patient samples, PLA1A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PLA1A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and SKIN.
